The poster presentation reviews the results of pre-clinical research on the company's dual E-selectin/CXCR4 antagonist GMI-1359. The data presented will show that GMI-1359 in combination with an antibody against the cancer regulatory programmed death receptor ligand, PD-L1, shortened time to complete tumor regressions in an animal model of colon cancer. The combination therapy also selectively reduced regulatory T cells (a class of lymphocytes that suppress immune responses) in the tumor, and created a more favorable immune-mediated anti-tumor environment.
"We are very pleased to announce these results, which show the possible
synergy between GMI-1359 and PD-L1 antagonists to treat solid tumors.
This is encouraging given PD-L1's key role in inhibiting the immune
response and allowing tumor growth," said
GMI-1359 is now in a Phase 1 clinical trial. Previous research on
GMI-1359 has been shared at annual meetings of the
Details of the poster at SITC, including session time and location, are below:
Poster (All poster sessions are in the
Abstract 209—Combination of a glycomimetic antagonist to
E-selectin and CXCR4, GMI-1359, with an anti-PD-L1 antibody attenuates
regulatory T cell infiltration and accelerates time to complete response
in the murine CT26 tumor model.
The meeting abstracts are available at SITC's website.
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development of its drug candidate GMI-1359. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors, including the availability and
timing of data from ongoing clinical trials, the uncertainties inherent
in the initiation of future clinical trials, whether interim results
from a clinical trial will be predictive of the final results of the
trial or results of early clinical trials will be indicative of the
results of future trials, expectations for regulatory approvals,
availability of funding sufficient for GlycoMimetics' foreseeable and
unforeseeable operating expenses and capital expenditure requirements,
other matters that could affect the availability or commercial potential
of GlycoMimetics' drug candidates and other factors discussed in the
"Risk Factors" section of GlycoMimetics' Annual Report on Form 10-K that
was filed with the
News Provided by Acquire Media